These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12471625)

  • 21. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
    Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
    J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation and coexpression of HIFs and NOTCH markers in NSCLC.
    Andersen S; Donnem T; Al-Saad S; Al-Shibli K; Stenvold H; Busund LT; Bremnes RM
    Anticancer Res; 2011 May; 31(5):1603-6. PubMed ID: 21617216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
    J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
    Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
    Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
    Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma.
    Al-Shibli K; Al-Saad S; Donnem T; Persson M; Bremnes RM; Busund LT
    Histopathology; 2009 Sep; 55(3):301-12. PubMed ID: 19723145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.
    Scieglinska D; Gogler-Piglowska A; Butkiewicz D; Chekan M; Malusecka E; Harasim J; Habryka A; Krawczyk Z
    Anticancer Res; 2014 Jun; 34(6):2833-40. PubMed ID: 24922646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.
    Myong NH
    J Korean Med Sci; 2005 Oct; 20(5):770-6. PubMed ID: 16224150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of maspin in non-small-cell lung cancer: correlation with clinical features.
    Takanami I; Abiko T; Koizumi S
    Clin Lung Cancer; 2008 Nov; 9(6):361-6. PubMed ID: 19073519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
    Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
    Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Turley H; Talks K; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 2001 Sep; 85(6):881-90. PubMed ID: 11556841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
    Volm M; Koomägi R
    Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
    Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
    Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
    Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.